今年以来，港股市场表现亮眼，截至6月11日收盘，恒生指数、恒生科技指数累计涨幅均超21%，恒生 指数成分股中总市值超1万亿港元的股票均上涨，涨幅最大的比亚迪股份累计涨逾60%，总市值最大的 腾讯控股累计涨逾25%。南向资金持续加仓港股市场，今年以来累计净流入超6700亿港元，创历史同期 新高。 近日，中信证券、华泰证券、国泰海通等多家券商机构召开2025年中期策略会。对于下半年的港股市 场，机构人士认为，国内政策发力驱动基本面修复，港股有望延续震荡向上趋势，南向资金在下半年仍 将持续增配港股市场，红利、科技、新消费等方向有望受青睐。 港股市场表现亮眼 在DeepSeek引领中国资产重估叙事的大背景下，今年以来港股市场表现全球领先。不过，受海外因素 扰动，其在4月一度出现明显回调。 截至6月11日收盘，恒生指数、恒生中国企业指数、恒生科技指数今年以来分别累计上涨21.47%、 21.62%、22%，领涨全球主要市场。 ● 本报记者 吴玉华 胡雨 对于今年以来港股市场上涨的原因，中金公司研究部海外策略首席分析师刘刚认为，当前中国有结构亮 点的宏观与市场环境更有利于港股，这是因为无论是提供稳定回报的分红，还是作为结 ...

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **pharmaceutical industry**, particularly the development and investment opportunities in **innovative drugs** and related sectors [1][3][5]. Core Insights and Arguments - **Government Support for Innovative Drugs**: The national policy emphasizes the development of innovative drugs, with various provinces implementing supportive measures, leading to increased market expectations for growth potential in innovative drug companies [1][3][5]. - **Optimized Drug Procurement Policies**: The government has indicated a positive shift in drug procurement policies, which is expected to benefit the generic drug sector and establish a policy bottom for the pharmaceutical industry [1][4]. - **High Pricing of Innovative Drugs**: The pricing of innovative drugs should align with their clinical value, promoting compliance in their use within hospitals and enhancing the commercialization of clinically valuable drugs [1][7]. - **Market Potential for GLP-1 Drugs**: The GLP-1 weight loss drug market is projected to exceed **$200 billion**, with significant opportunities in the supply chain, particularly for domestic companies in the GLP-1 receptor agonist sector [1][8][9]. - **Investment Opportunities in Chemical Reagents**: The synthesis of drugs requires substantial chemical reagents and raw materials, presenting investment opportunities in leading companies that are expected to see clear performance and valuation growth over the next 3 to 5 years [1][10]. Additional Important Content - **Impact of Medical Reform**: Future medical reforms will continue to drive both incremental innovation and optimization of existing products, enhancing the overall quality and compliance of the pharmaceutical industry [6][12]. - **Geopolitical Risks**: The geopolitical landscape may create volatility in stock prices, but domestic companies in the GLP-1 sector are well-positioned due to their strong production capabilities [9][11]. - **AI in Healthcare**: The integration of AI in healthcare is seen as a slow variable that will enhance efficiency in drug development, although its immediate impact on profitability is limited [13][14]. - **Consumer Market Dynamics**: The pharmaceutical sector is characterized by rigid demand, with growth opportunities in outpatient self-pay markets and specific segments like ophthalmology and aesthetic medicine [16][19]. - **Valuation Recovery**: The recovery of valuations in the pharmaceutical sector is contingent on improvements in the macroeconomic environment, with a focus on segments that can command brand premiums [18][19]. This summary encapsulates the key points discussed in the conference call, highlighting the current state and future prospects of the pharmaceutical industry, particularly in the context of innovative drugs and market dynamics.

Investment Rating - The industry investment rating is "Overweight" (maintained) [5] Core Viewpoints - The report highlights the upcoming 85th Annual Scientific Sessions of the American Diabetes Association (ADA) from June 20-23, 2025, which is expected to showcase significant advancements in GLP-1 class drugs and weight management strategies [5][6] - The report emphasizes the increasing international recognition of China's innovations in the endocrine and metabolic fields, particularly in the GLP class drug sector, with notable achievements from companies like Innovent Biologics and Eli Lilly [7][8] - The report anticipates a substantial growth in China's GLP-1 weight loss drug market, projecting a market size exceeding 15 billion yuan by 2025, with penetration rates expected to rise from under 5% in 2023 to 18%-20% [8] Summary by Sections Recent Industry Performance - The industry has shown relative returns of 8.85% over the past month, 10.28% over the past three months, and 3.81% over the past year compared to the CSI 300 index [3] Investment Highlights - The report focuses on the catalysts from the ADA conference, particularly the advancements in GLP-1 class drugs, which are expected to drive investment opportunities [6][7] - Key companies mentioned include Eli Lilly, Novo Nordisk, and domestic firms like Boryung Pharmaceutical and Gan & Lee Pharmaceuticals, which are actively involved in GLP-1 drug development [7][8] Market Dynamics - The report notes the active business development transactions in the GLP class drug sector, indicating a high level of industry enthusiasm and potential for growth [7] - It also mentions the upcoming global diabetes-related conferences in 2025, which will further stimulate the market for GLP class drugs [8]

Investment Rating - The report maintains a "Buy" rating for Hansoh Pharmaceutical (03692) despite a year-to-date stock price increase of 53% [1] Core Insights - UBS believes that the stock price of Hansoh Pharmaceutical is still undervalued, raising the target price from HKD 24 to HKD 33.3 [1] - The positive outlook is driven by the company's R&D capabilities and revenue potential from collaboration projects, particularly the licensing agreements for BD HS-20094 and HS-10535 [1] - Earnings per share forecasts for Hansoh Pharmaceutical have been increased by 16.2%, 17.7%, and 21.3% for the years 2025 to 2027, with revenue forecasts adjusted upward by 6% to 12% [1] - The main growth drivers are expected to be Aumolertinib and BD, with projected sales for Aumolertinib reaching RMB 6 billion this year and potentially exceeding RMB 8 billion by 2029 [1]

Core Insights - The total trading volume of non-monetary ETFs reached 272.705 billion CNY, with 62 ETFs exceeding 1 billion CNY in trading volume [1] - The Hong Kong Innovative Drug ETF, Short-term Bond ETF, and Credit Bond ETF led the market in trading volume, with respective volumes of 13.208 billion CNY, 12.052 billion CNY, and 9.988 billion CNY [1] - The Hong Kong Innovative Drug ETF (513120.SH) has a latest share size of 9.148 billion CNY and closely tracks the Hong Kong Innovative Drug CNY Index [1] Trading Volume and Performance - The Hong Kong Innovative Drug ETF saw a trading volume increase of 166.52% compared to the previous trading day, with an average trading volume of 5.319 billion CNY over the last 5 days [2] - The Short-term Bond ETF (511360.SH) also experienced a trading volume increase of 22.23% compared to the previous trading day, with a latest share size of 433 million CNY [2] - The Hong Kong Innovative Drug ETF Fund (520700.SH) had a trading volume increase of 328.35% compared to the previous trading day, with a latest share size of 256 million CNY [3] Turnover Rate - The Benchmark National Debt ETF had the highest turnover rate at 460.37%, followed by the Hong Kong Medical ETF at 394.29% and the Hong Kong Innovative Drug ETF Fund at 261.80% [7] - The Hong Kong Innovative Drug ETF also showed a significant increase in turnover rate, rising by 143.03% compared to the previous trading day [2] Sector and Index Tracking - The Hong Kong Innovative Drug ETF tracks the Hong Kong Innovative Drug CNY Index, which includes up to 50 listed companies involved in innovative drug research and development [1] - The Short-term Bond ETF tracks the China Securities Short-term Bond Index, reflecting the overall performance of investment-grade short-term bonds [2] - The Hong Kong Medical ETF tracks the Hong Kong Stock Connect Medical Care Index, which includes companies involved in pharmaceuticals, biotechnology, and medical services [9]

Group 1 - The U.S. and India are expected to reach a temporary trade agreement by the end of the month, while the U.S. and Mexico are nearing an agreement on steel import tariffs [12] - The European Union proposed to lower the price cap on Russian oil to $45, with Putin announcing an extension of countermeasures [12] - The U.K. is fully pricing in two interest rate cuts by the Bank of England within the year due to a significant drop in employment numbers [12] Group 2 - The U.S. stock market saw all three major indices close higher, with the Dow Jones up 0.25%, S&P 500 up 0.55%, and Nasdaq up 0.6% [4] - In the Hong Kong market, the Hang Seng Index opened high but closed down 0.08%, with significant movements in sectors like aviation and rare earths [5] - The A-share market experienced a decline, with the Shanghai Composite Index down 0.40% and the Shenzhen Component down 0.86%, amid a chaotic market environment [6] Group 3 - The price of spot gold closed at $3322.6 per ounce, down 0.09%, while spot silver closed at $36.53 per ounce, down 0.63% [7] - WTI crude oil closed at $64.47 per barrel, down 0.14%, and Brent crude oil closed at $66.72 per barrel, down 0.09% [7]

2025年已行至年中，港股市场在经历上半年"脉冲式反弹"后，下半年走势成为投资者关注焦点。 此外，港股估值水平长期处于相对低位，也是今年上半年港股市场走强的原因之一。据中信证券研究， 目前港股整体估值水平相对合理，成长板块的估值处于历史相对较低水平。在国内经济持续复苏，AI 对业绩催化的预期下，以及预计更多优质企业赴港上市的背景下，下半年港股整体的估值水平仍有望进 一步抬升。 多家券商机构展望下半年行情 对于下半年的港股市场行情，中信证券认为，尽管关税政策仍可能对港股基本面造成影响，但近期关税 扰动缓和已带来市场情绪的抬升，且中美贸易摩擦对港股基本面影响相对有限，企业盈利仍具韧性；而 在港股上市制度改革深化的背景下，预计优质企业赴港上市也将进一步提升港股市场的资产质量及流动 性水平；南向资金或也将持续流入港股市场带来支撑。考虑到中美博弈仍具复杂性，且外围市场不确定 性尚存，三季度港股或呈震荡向上的趋势。而四季度预计随着国内稳增长政策的加码带来港股业绩上修 的契机；以及AI产业催化的落地重塑科技板块估值，叠加全球流动性环境改善，港股或迎来估值和盈 利的双重修复。 中金公司表示，当前中国整体仍需修复但有结构亮点的 ...

2025年已行至年中，港股市场在经历上半年"脉冲式反弹"后，下半年走势成为投资者关注焦点。 近日，中金公司、中信证券、国泰海通等多家券商机构发布了港股下半年策略报告，多家机构认为，港股将延 续震荡向上趋势，高股息资产、科技互联网、新消费等方向有望受青睐。 多重因素推动港股市场走强 回顾今年上半年港股市场行情，在DeepSeek引领中国资产重估叙事的大背景下，港股表现全球领先。不过， 受美国所谓的"对等关税"扰动，市场在反弹与回调中循环往复。 截至目前，恒生指数年内涨幅为20.45%，恒生科技指数的年内涨幅为20.68%。个股方面，恒生指数成份股中 的石药集团、周大福、翰森制药、小米集团、比亚迪股份、药明生物、网易等多股年内涨幅超过50%。 今年上半年，DeepSeek引发AI热潮助推中国资产重估，推动港股市场一度领涨全球，随后，由于部分中国科 技龙头股的资本开支计划不及预期，科技重估叙事有所降温。中金公司认为，后续需要更多催化剂，尤其是跨 越式的模型迭代或突破性的应用落地。中短期来看，AI趋势主要通过拉动资本开支推动私人部门信用扩张， 2025年AI相关新增资本开支预计约1500亿元。 中金公司表示，当前中国 ...

Group 1: Company Overview - He Mei Pharmaceutical Co., Ltd. (和美药业) is an innovative biopharmaceutical company established in 2002, focusing on the discovery and development of small molecule drugs for autoimmune diseases and tumors [1][2] - The company has submitted an application for listing on the Hong Kong Stock Exchange, with Guo Zheng International as its exclusive sponsor [1] Group 2: Product Pipeline - He Mei Pharmaceutical has developed seven small molecule drug candidates targeting autoimmune and tumor diseases, with four candidates in Phase II, III clinical trials, or NDA stages [2][8] - The core product, Mufemilast, is a novel small molecule PDE4B inhibitor with potential applications in various autoimmune diseases, including psoriasis and inflammatory bowel disease [3][5] Group 3: Market Potential - The autoimmune disease drug market in China has grown from $2.5 billion in 2019 to $4 billion in 2023, with a compound annual growth rate (CAGR) of 12.5% [5] - The psoriasis drug market in China reached ¥13.9 billion in 2023, with a CAGR of 30.4% from 2019 to 2023, and is expected to grow to ¥89.4 billion by 2032, with a CAGR of 59.1% [5] Group 4: Clinical Development - Mufemilast is the only drug that can be directly used for psoriasis patients with latent tuberculosis infection, with its safety supported by Phase III clinical trials [3][5] - Hemay022, another core product, is a dual-target small molecule inhibitor for advanced breast cancer, currently undergoing a Phase III clinical trial [7] Group 5: Financial Overview - The company reported a pre-tax loss of ¥156.4 million in 2023 and ¥123.4 million in 2024, primarily due to R&D and administrative expenses [12][13] - As of the end of 2024, the company had cash and cash equivalents of ¥150 million, with a net cash outflow from operating activities of ¥141 million in 2023 [11][12]

Core Viewpoint - The medical-themed funds have shown a significant recovery in 2025, with over 90% of the 286 funds achieving positive returns, and some funds exceeding a 50% increase [1][3][4]. Group 1: Fund Performance - As of June 9, 2025, 260+ medical-themed funds reported positive returns, with 200 funds increasing over 10%, 144 funds over 20%, and 86 funds over 30% [3][4]. - The top-performing funds include 中银港股通医药A (72.23%), 中银港股通医药C (71.63%), and 鹏华医药科技A (64.80%) [1]. - The Hang Seng Medical Care Index, representing Hong Kong innovative drugs, has risen over 50%, outperforming other indices [4]. Group 2: Market Dynamics - The recovery is attributed to the significant undervaluation of many stocks, particularly in the Hong Kong pharmaceutical sector, following four years of decline [2]. - The Chinese innovation drug sector has matured over the past decade, supported by favorable domestic policies, leading to a resurgence in related funds [2][5]. - The performance of medical-themed funds has shown notable differentiation, with a performance gap exceeding 70 percentage points between the best and worst funds [4]. Group 3: Investment Focus - The top holdings of high-performing funds include companies like 翰森制药, 科伦博泰生物-B, and 百济神州, which are recognized for their innovative drug development [6][7]. - The industry is witnessing a shift towards innovative drugs, with significant orders being placed for Chinese companies involved in early-stage research and development [5]. - Analysts express optimism about the Chinese pharmaceutical industry's capabilities in areas like ADC, dual antibodies, and cell therapy, positioning it at the forefront of global innovation [8][9].